InvestorsHub Logo
Followers 48
Posts 3935
Boards Moderated 0
Alias Born 01/26/2011

Re: mrpatinmn post# 142203

Wednesday, 09/25/2013 1:08:42 PM

Wednesday, September 25, 2013 1:08:42 PM

Post# of 346460
Mrpatinmn, Roche did NOT get a BTD for NSCLC

Roche got its ALK-inhibitor anointed with a BTD for a subset of patients in NSCLC that include up to 5% of the total NSCL patient population.

Upto 5% of non-squamous NSCLC carry ALK gene rearrangements.


http://www.mplnet.com/strategic-ordering/non-small-cell-lung-cancer

Not only that, but Novartis' LDK378 has also received a BTD for ALK+ NSCLC months ago.

So this really has a marginal impact on the potential market for bavi in 2nd line NSCLC, if any considering that if these are used as first line treatments then bavi would still be an option as a 2nd line treatment.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News